SG11201901830UA - nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS - Google Patents
nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODSInfo
- Publication number
- SG11201901830UA SG11201901830UA SG11201901830UA SG11201901830UA SG11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA
- Authority
- SG
- Singapore
- Prior art keywords
- utah
- nnif
- international
- suite
- salt lake
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
WO 18/0 45 37 1 A3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) W I PO I PC T omit ° oI0IIIIIIIIIIH1011 111EI111°111 (10) International Publication Number WO 2018/045371 A3 (51) International Patent Classification: A61K 38/00 (2006.01) A61K 47/60 (2017.01) A61K 38/57 (2006.01) CO7K 14/47 (2006.01) A61K 47/48 (2006.01) (21) International Application Number: PCT/US2017/050072 (22) International Filing Date: 05 September 2017 (05.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/383,243 02 September 2016 (02.09.2016) US 62/492,019 28 April 2017 (28.04.2017) US (71) Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). (72) Inventors: YOST, Christian Con; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). ZIMMER- MAN, Guy A.; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). WEYRICH, Andrew S.; 615 Ara- peen Drive, Suite 310, Salt Lake City, Utah 84108 (US). SCHIFFMAN, Joshua; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). (74) Agent: GIDDINGS, Barton W.; STOEL RIVES LLP, 201 So. Main Street, Suite 1100, One Utah Center, Salt Lake City, Utah 84111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 12 April 2018 (12.04.2018) (54) Title: nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS 100 80 - 60 - 40 - 20 - 0 0 I Percent survival 10 20 30 40 50 Hours No treatment FIG. 9A LPS CRISPP-LPS nNIF-LPS CRISPP-SCR-LPS (57) : Neonatal NET-Inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383243P | 2016-09-02 | 2016-09-02 | |
| US201762492019P | 2017-04-28 | 2017-04-28 | |
| PCT/US2017/050072 WO2018045371A2 (en) | 2016-09-02 | 2017-09-05 | nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901830UA true SG11201901830UA (en) | 2019-03-28 |
Family
ID=61309026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901830UA SG11201901830UA (en) | 2016-09-02 | 2017-09-05 | nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10857201B2 (en) |
| EP (1) | EP3506924A4 (en) |
| JP (1) | JP2019534247A (en) |
| KR (1) | KR20190045271A (en) |
| CN (1) | CN109937047A (en) |
| AU (1) | AU2017321965A1 (en) |
| BR (1) | BR112019004299A2 (en) |
| CA (1) | CA3035770A1 (en) |
| MX (1) | MX2019002479A (en) |
| RU (1) | RU2019109049A (en) |
| SG (1) | SG11201901830UA (en) |
| WO (1) | WO2018045371A2 (en) |
| ZA (1) | ZA201901942B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11324801B2 (en) | 2016-09-02 | 2022-05-10 | University Of Utah Research Foundation | NNIF and nNIF-related peptides and related methods |
| WO2021226111A1 (en) * | 2020-05-04 | 2021-11-11 | University Of Utah Research Foundation | Immunothrombosis in covid-19 acute respiratory distress syndrome |
| CN117004744B (en) * | 2022-04-27 | 2024-05-24 | 数字碱基(南京)科技有限公司 | Lung cancer prognosis evaluation method and model based on plasma microorganism DNA characteristics |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
| US9308235B2 (en) * | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| EP4219534A3 (en) * | 2013-07-08 | 2023-09-27 | The University of Utah Research Foundation | Methods for treatment of and prophylaxis against inflammatory disorders |
-
2017
- 2017-09-05 CN CN201780067221.2A patent/CN109937047A/en active Pending
- 2017-09-05 EP EP17847679.2A patent/EP3506924A4/en active Pending
- 2017-09-05 US US16/328,697 patent/US10857201B2/en active Active
- 2017-09-05 AU AU2017321965A patent/AU2017321965A1/en not_active Abandoned
- 2017-09-05 SG SG11201901830UA patent/SG11201901830UA/en unknown
- 2017-09-05 MX MX2019002479A patent/MX2019002479A/en unknown
- 2017-09-05 CA CA3035770A patent/CA3035770A1/en active Pending
- 2017-09-05 KR KR1020197009122A patent/KR20190045271A/en not_active Application Discontinuation
- 2017-09-05 JP JP2019512681A patent/JP2019534247A/en active Pending
- 2017-09-05 WO PCT/US2017/050072 patent/WO2018045371A2/en unknown
- 2017-09-05 RU RU2019109049A patent/RU2019109049A/en unknown
- 2017-09-05 BR BR112019004299A patent/BR112019004299A2/en not_active IP Right Cessation
-
2019
- 2019-03-28 ZA ZA2019/01942A patent/ZA201901942B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019004299A2 (en) | 2019-05-28 |
| WO2018045371A3 (en) | 2018-04-12 |
| WO2018045371A2 (en) | 2018-03-08 |
| US10857201B2 (en) | 2020-12-08 |
| RU2019109049A3 (en) | 2020-12-24 |
| KR20190045271A (en) | 2019-05-02 |
| ZA201901942B (en) | 2020-10-28 |
| AU2017321965A1 (en) | 2019-04-04 |
| CN109937047A (en) | 2019-06-25 |
| CA3035770A1 (en) | 2018-03-08 |
| MX2019002479A (en) | 2019-09-19 |
| EP3506924A2 (en) | 2019-07-10 |
| EP3506924A4 (en) | 2020-05-20 |
| RU2019109049A (en) | 2020-10-05 |
| JP2019534247A (en) | 2019-11-28 |
| US20190201487A1 (en) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810443SA (en) | Invasive medical devices including magnetic region and systems and methods | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201408261UA (en) | Syringe | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201900442PA (en) | Sorting of t lymphocytes in a microfluidic device | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
| SG11201903786UA (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| SG11201408171SA (en) | Fbxo3 inhibitors | |
| SG11201901673SA (en) | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers |